Stay updated with breaking news from Doug Schultz. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
When given early, lab-engineered antibody infusions have reduced COVID-19 hospitalizations among persons at high risk. Previous versions of these treatments do not appear to work against the omicron variant, however. Replacement products are in short supply, with providers given a few dozen treatments weekly while managing hundreds of new patients.
When given early, lab-engineered antibody infusions have reduced COVID-19 hospitalizations among persons at high risk. Previous versions of these treatments do not appear to work against the omicron variant, however. Replacement products are in short supply, with providers given a few dozen treatments weekly while managing hundreds of new patients.
When given early, lab-engineered antibody infusions have reduced COVID-19 hospitalizations among persons at high risk. Previous versions of these treatments do not appear to work against the omicron variant, however. Replacement products are in short supply, with providers given a few dozen treatments weekly while managing hundreds of new patients.
When given early, lab-engineered antibody infusions have reduced COVID-19 hospitalizations among persons at high risk. Previous versions of these treatments do not appear to work against the omicron variant, however. Replacement products are in short supply, with providers given a few dozen treatments weekly while managing hundreds of new patients.
When given early, lab-engineered antibody infusions have reduced COVID-19 hospitalizations among persons at high risk. Previous versions of these treatments do not appear to work against the omicron variant, however. Replacement products are in short supply, with providers given a few dozen treatments weekly while managing hundreds of new patients.